Persons with hemophilia in the United States, Latin
America, Europe, Asia, the Middle East and Africa were
infected with contaminated blood products. Lieff Cabraser
is representing clients from around the world in lawsuits
filed in U.S. courts against American blood companies
that sold in the U.S. and exported contaminated blood
worldwide.
Blood
Factor Lawsuit Update - August 2004
In
December 2003, the United States Judicial Panel on Multidistrict
Litigation (MDL) transferred the federal blood factor class
action lawsuit filed by Lieff Cabraser Heimann & Bernstein,
LLP, Gullone, et al. v. Bayer, et al., from the Northern
District of California in Oakland to the Northern District
of Illinois in Chicago, as part of In re Factor VIII or
IX Concentrate Blood Products Litigation, MDL No. 986,
which we refer to as the MDL.
The
case is now before the Honorable John F. Grady. Judge Grady
oversaw the litigation by Americans with hemophilia who contracted
HIV from defendants blood factor concentrates during
the 1980s. Judge Grady is familiar with many of the issues
that will arise in this case.
In
March 2004, Judge Grady appointed Lieff Cabraser as lead counsel
in the blood factor litigation. As lead counsel, Lieff Cabraser
will guide the litigation effort and coordinate all plaintiffs
counsel participating in the MDL.
The
plaintiffs and defendants in the blood factor litigation are
presently engaged in a preliminary discovery stage
of the lawsuit. Discovery involves the exchange
of information between parties. As part of plaintiffs
discovery, plaintiffs seek to obtain documents and other information
from the defendants to strengthen the case against the defendants
on subjects on which the Court has allowed discovery.
As
part of defendants discovery, each plaintiff must submit
a Preliminary Patient Profile Form (PPF) by September
17, 2004. The PPF is a signed, sworn statement that summarizes
each plaintiffs case, contains relevant personal information,
and identifies the brand or manufacturer of the factor concentrate
plaintiffs used, the dates of use, and the source of the product(s)
(hospital, pharmacy, clinic, or other supplier). Judge Grady
issued an order on March 17, 2004, regarding this discovery.
At
this time, plaintiffs counsel in the MDL are assisting
with the production of PPFs for each retained client. People
who are not represented at this time are not bound by the
September 17, 2004 deadline to submit a PPF, but should act
quickly to retain counsel and/or submit a PPF, or risk being
potentially unable to bring a claim. Although Gullone
was filed as a class action, the Court has stated it will
likely decline to certify a class, and, at this time, only
those plaintiffs who are represented in the litigation will
benefit from any potential judgment.
After
the September 17 deadline for submission of the PPFs, Judge
Grady will likely hear a motion to dismiss the class allegations
and to dismiss foreign plaintiffs claims for alleged
lack of jurisdiction. Plaintiffs counsel is preparing
to oppose these motions. However, if the class allegations
are dismissed, the lawsuit will still proceed for all plaintiffs
who are represented.
If
any foreign claims are dismissed pursuant to the doctrine
of forum non conveniens, the dismissal could be conditional,
and the claimants may still elect to proceed in another jurisdiction.